Pharmaceutical Product Development, (PPD) has completed an expansion of its clinical supplies facility in Athlone, Ireland, that will enable the company to double its packaging warehousing capabilities and quadruple its distribution services. Those increases are the result of PPD more than tripling the size of the facility as part of its long-term strategy to expand its global depot network.
Scientifically Adept - Platform Agnostic: Particle Sciences Positions Itself as a Bioavailability Tool for Most Dosage FormsJanuary 22, 2015 11:50 am | by Mike Auerbach, Editor In Chief | Articles | Comments
Particle Sciences, a drug development services company located in Bethlehem, Pennsylvania, has...
Catalent Expands Integrated Softgel Operations Through Coating and Packaging Investment In Eberbach, GermanyJanuary 22, 2015 10:44 am | News | Comments
Catalent Pharma Solutions will adding new coating and blister packaging equipment at its 360,000...
The Pharma & Biopharma Outsourcing Association (PBOA) today announced that Nelson Patterson...
Catalent Pharma Solutions and Mitsubishi Gas Chemical Company, Inc. (MGC), have entered into a partnership agreement to co-promote Catalent’s proprietary GPEx® technology in the Asian market.
AMRI has received a 10-year federal contract award from the NIH for drug development and manufacturing services. This NIH/National Institute of Neurological Disorders and Stroke award will support NIH's Drug Manufacturing and Formulation Program, which is a component of the Blueprint Neurotherapeutics Network. AMRI has supported the NIH BPN since 2011, providing chemistry services and discovery technologies.
Boehringer Ingelheim and Sanofi announced today that they enter into an alliance to extend Sanofi’s manufacturing capacity network for therapeutic monoclonal antibodies.
SGS Life Science Services today announced that its laboratory in Poitiers, France, has successfully completed a full analytical validation of the novel Meso Scale Discovery (MSD®) V-PLEX 10-plex Proinflammatory Panel I, for use with human plasma samples.
AMRI has announced that Michael M. Nolan, senior vice president and chief financial officer, will be departing AMRI. Nolan will remain with AMRI through February 2015 to support an orderly transition.The company also announced that Felicia Ladin will join the company in the same role, effective February 4, 2015.
This novel technology uses lipid-like counter-ion salts to improve the solubility of drugs in lipid-based liquid, semi-solid and multiparticulate formulations. This technology adds to Capsugel Dosage Form Solutions’ growing suite of bioavailability enhancement technologies and capabilities.
AMRI will initially provide cGMP manufacture and analytical support for the registration of five product candidates. AMRI will be reimbursed for technology transfer activities, analytical development and manufacture of regulatory submission batches. In addition, AMRI is eligible to receive additional payments for achieving product delivery milestones.
Aptuit has divested its aseptic clinical manufacturing site in Glasgow, UK to Albany Molecular Research, Inc., and has entered into a definitive agreement with AMRI to acquire the West Lafayette, Indiana solid-state chemistry business for a total consideration of $60 million.
Pharmaceutical Product Development and Shin Nippon Biomedical Labs have formed a joint venture that will provide a full range of clinical development services in Japan, including Phase I-IV clinical trial monitoring, project management, site intelligence and activation, biostatistics, data management, medical writing, pharmacovigilance, regulatory and FSP services.
Bayer HealthCare and Cardinal Health have signed a 15-year agreement for the contract manufacturing of Xofigo. As part of the agreement, Cardinal Health will build a state-of-the art, 64,000 square foot facility in Indianapolis, which will be dedicated exclusively to the manufacturing of Xofigo.
The non-profit New England CRO/CMO Council is open to CROs and CMOs operating in and around Boston, the nation's largest life sciences cluster. The Council is designed to market the cluster and to provide the broader BioPharma community with a means of accessing local CRO’s, CMOs and other suppliers to meet their current and future outsourcing requirements.
Pharmaceutical Product Development and ERT today announced a strategic partnership to facilitate delivery of ERT’s comprehensive solutions for patient safety and efficacy endpoint data collection to help biopharmaceutical clients conduct clinical trials in a more efficient and cost-effective manner.
Scilabs Nutraceuticals Inc., a contract manufacturer of nutraceuticals based in Irvine, California, has commented on the recent consent decree that it entered into with the FDA, in which the company agreed to suspend nutraceutical manufacturing operations.
Vetter has announced that its U.S. early-stage development site located at the Illinois Science + Technology Park in suburban Chicago, has completed the next step of its expansion with the addition of a third cleanroom. Clinical syringe projects are now being accepted at the facility, which can handle preclinical through phase II projects.
Avid Bioservices, the contract manufacturing subsidiary of Peregrine Pharmaceuticals, has initiated an expansion of its biomanufacturing capacity. The new production facility will more than double Avid Bioservices' current manufacturing capacity in a state-of-the-art facility design.
Vetter has announced the opening of a new representative office in Singapore. The announcement was made at a ceremony attended by members of local government agencies and a number of executives of pharmaceutical/biotech companies with a presence in the Asian region, as well as Vetter executives.
Eurofins Scientific has announced the pending acquisition of SF Analytical (SFA) Laboratories. The transaction will close at the end of November. The acquisition strengthens Eurofins' growing presence in the US, as well as expands the current base of operations in the Midwestern United States.
GVK BIO has announced the signing of a definitive agreement to acquire Vanta Bioscience, a full service preclinical GLP toxicology and safety assessment contract research organization operating out of Chennai, India.
Catalent Pharma Solutions has announced that work has commenced to expand its highly potent and cytotoxic clinical drug packaging capabilities within its 450,000 sq. ft. Kansas City, MO campus.
LabCorp will pay about $6.1 billion in cash and stock to buy Covance in a tie-up that aims to improve clinical trial research for pharmaceuticals.
Impax Laboratories has announced a reorganization of its research and development (R&D) organizations and a prioritization of the project portfolios within the generic and brand businesses
The Pharma & Biopharma Outsourcing Association (PBOA), a new non-profit trade association devoted to advancing the interests of CMOs, CDMOs and other service providers, has elected Peter Bigelow to serve as Chairman of the Board of Trustees.
An expert scientist in pharmaceutical formulation development at Metrics Contract Services has been awarded a patent for intellectual property about controlled release technology.
Catalent today announced the promotion of Australia Country General Manager, Mark Bisset, to President, Catalent Asia Pacific. He succeeds David Heyens who has announced that he plans to retire from Catalent on December 31st 2014.
Q. Dwight Lewis is responsible for managing all quality-related functions to ensure that Mayne Pharma’s U.S. pharmaceutical operations – which range from laboratories to manufacturing lines – continue to comply with global regulatory agency and industry standards.
- Page 1